![Mark Enyedy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Net worth: 770 035 $ as of 29/04/2026
Mark Joseph Enyedy is currently an Independent Director at BioMarin Pharmaceutical, Inc. since 2023, an Independent Director at Charles River Laboratories International, Inc. starting in 2025, and an Independent Outside Director at Astellas Pharma, Inc. starting in 2025.
Formerly, Mr. Enyedy was President, Chief Executive Officer & Director at ImmunoGen, Inc. from 2016 to 2024; Chief Executive Officer & Director at Proteostasis Therapeutics, Inc. from 2011 to 2013; Independent Director at Keryx Biopharmaceuticals, Inc. from 2017 to 2018; Independent Director at Akebia Therapeutics, Inc. from 2018 to 2021; Director at Biotechnology Innovation Organization; Director at American Cancer Society, New England Division, Inc.; Independent Director at Fate Therapeutics, Inc. from 2013 to 2018; Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022; Independent Non-Executive Director at Ergomed Group Ltd. from 2021 to 2023; SVP, President-Transplant & Multiple Sclerosis at Genzyme Corp.
from 2011 to 2012; Executive VP & Head-Corporate Development at Shire Plc from 2014 to 2016; and Associate at Palmer & Dodge LLP.
Education includes undergraduate studies at Northeastern University and graduate studies at Harvard Law School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 07/05/2026 | 2,384 ( 0% ) | 398 056 $ | 29/04/2026 | |
| 06/04/2026 | 6,900 ( 0% ) | 371 979 $ | 29/04/2026 |
| Companies | Position | Start |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Director/Board Member | 26/12/2023 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Director/Board Member | 19/05/2025 |
| ASTELLAS PHARMA INC. | Director/Board Member | 18/06/2025 |
| Companies | Position | End |
|---|---|---|
| IMMUNOGEN, INC. | Chief Executive Officer | 31/12/2023 |
| ERGOMED | Director/Board Member | 12/11/2023 |
| LOGICBIO THERAPEUTICS, INC. | Director/Board Member | 15/11/2022 |
| AKEBIA THERAPEUTICS, INC. | Director/Board Member | 01/06/2021 |
| KERYX BIOPHARMACEUTICALS | Director/Board Member | 11/12/2018 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 17 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Charles River Laboratories International, Inc.
 Charles River Laboratories International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides laboratory testing and research services on a contract basis | Commercial Services |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Palmer & Dodge LLP
 Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma, Inc.
 Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Akebia Therapeutics, Inc.
 Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Fate Therapeutics, Inc.
 Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Develops disease-modifying therapeutics for orphan and neurodegenerative diseases | Health Technology |
American Cancer Society, New England Division, Inc. | |
Harvard Law School
 Harvard Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ergomed Plc
 Ergomed Plc BiotechnologyHealth Technology Engages in research and development of drugs for oncology & rare diseases | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
